Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Description: Unconjugated Mouse monoclonal to PD-L1 (AS1A7)

Description: CD274 / PD-L1 Peptide

Description: (IN) PD-L1 peptide

Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

Description: Antibody raised against PD-L1/CD274

Description: Antibody raised against PD-L1/CD274

Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA

Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.